178 related articles for article (PubMed ID: 16397288)
1. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Khosravan R; Grabowski BA; Mayer MD; Wu JT; Joseph-Ridge N; Vernillet L
J Clin Pharmacol; 2006 Jan; 46(1):88-102. PubMed ID: 16397288
[TBL] [Abstract][Full Text] [Related]
2. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Khosravan R; Kukulka MJ; Wu JT; Joseph-Ridge N; Vernillet L
J Clin Pharmacol; 2008 Sep; 48(9):1014-24. PubMed ID: 18635756
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Khosravan R; Grabowski BA; Wu JT; Joseph-Ridge N; Vernillet L
Clin Pharmacokinet; 2006; 45(8):821-41. PubMed ID: 16884320
[TBL] [Abstract][Full Text] [Related]
4. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment.
Hoshide S; Takahashi Y; Ishikawa T; Kubo J; Tsuchimoto M; Komoriya K; Ohno I; Hosoya T
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1117-8. PubMed ID: 15571212
[TBL] [Abstract][Full Text] [Related]
5. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
[TBL] [Abstract][Full Text] [Related]
6. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
Hosoya T; Ohno I
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S27-34. PubMed ID: 21654267
[TBL] [Abstract][Full Text] [Related]
7. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
Becker MA; Kisicki J; Khosravan R; Wu J; Mulford D; Hunt B; MacDonald P; Joseph-Ridge N
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1111-6. PubMed ID: 15571211
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease.
Small DS; Farid NA; Li YG; Ernest CS; Winters KJ; Salazar DE; Payne CD
J Clin Pharm Ther; 2009 Oct; 34(5):575-83. PubMed ID: 19744013
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.
Mayer MD; Khosravan R; Vernillet L; Wu JT; Joseph-Ridge N; Mulford DJ
Am J Ther; 2005; 12(1):22-34. PubMed ID: 15662289
[TBL] [Abstract][Full Text] [Related]
10. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
Bruce SP
Ann Pharmacother; 2006 Dec; 40(12):2187-94. PubMed ID: 17132810
[TBL] [Abstract][Full Text] [Related]
11. Urate-lowering therapy for gout: focus on febuxostat.
Love BL; Barrons R; Veverka A; Snider KM
Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
[TBL] [Abstract][Full Text] [Related]
12. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
Takai M; Yamauchi T; Ookura M; Matsuda Y; Tai K; Kishi S; Yoshida A; Iwasaki H; Nakamura T; Ueda T
Anticancer Res; 2014 Dec; 34(12):7287-96. PubMed ID: 25503162
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.
Grabowski BA; Khosravan R; Vernillet L; Mulford DJ
J Clin Pharmacol; 2011 Feb; 51(2):189-201. PubMed ID: 20354234
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.
Komoriya K; Hoshide S; Takeda K; Kobayashi H; Kubo J; Tsuchimoto M; Nakachi T; Yamanaka H; Kamatani N
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1119-22. PubMed ID: 15571213
[TBL] [Abstract][Full Text] [Related]
16. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets.
Abdallah H; Jerling M
J Clin Pharmacol; 2005 Jul; 45(7):802-9. PubMed ID: 15951470
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
18. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment.
Bramson C; Ouellet D; Roman D; Randinitis E; Gardner MJ
J Clin Pharmacol; 2006 Jan; 46(1):29-36. PubMed ID: 16397281
[TBL] [Abstract][Full Text] [Related]
19. FTY720 pharmacokinetics in mild to moderate hepatic impairment.
Kovarik JM; Schmouder RL; Serra D; Wang Y; Wiegand H; Dilzer SC; Lasseter KC
J Clin Pharmacol; 2005 Apr; 45(4):446-52. PubMed ID: 15778425
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment.
Peng JZ; Pulido F; Causemaker SJ; Li J; Lorenzo A; Cepeda C; GarcĂa Cabanillas JA; DaSilva B; Brun SC; Arribas J
J Clin Pharmacol; 2006 Mar; 46(3):265-74. PubMed ID: 16490802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]